ALB
MOLECULAR TARGETalbumin
ALB (albumin) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting ALB
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Warfarin | 2.08 | 7 |
| 2 | Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of | 1.95 | 6 |
| 3 | Tolbutamide | 1.10 | 2 |
| 4 | cbd | 0.69 | 1 |
| 5 | egcg | 0.69 | 1 |
| 6 | cannabidiol | 0.69 | 1 |
| 7 | Catechin | 0.69 | 1 |
| 8 | Evans Blue | 0.69 | 1 |
| 9 | Olmesartan Medoxomil | 0.69 | 1 |
| 10 | Phenylbutazone | 0.69 | 1 |
| 11 | Trazodone | 0.69 | 1 |
About ALB as a Drug Target
ALB (albumin) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented ALB interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
ALB inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.